BiotechTube

octreotide FluidCrystal® injection depot

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acromegaly

Conditions

Acromegaly, Neuroendocrine Tumors

Trial Timeline

Jan 1, 2015 → Jun 1, 2016

NCT ID
NCT02299089

About octreotide FluidCrystal® injection depot

octreotide FluidCrystal® injection depot is a phase 2 stage product being developed by Novartis for Acromegaly. The current trial status is completed. This product is registered under clinical trial identifier NCT02299089. Target conditions include Acromegaly, Neuroendocrine Tumors.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02299089Phase 2Completed

Competing Products

20 competing products in Acromegaly

See all competitors
ProductCompanyStageHype Score
AlesseNovartisPhase 2
52
ONO-5788 + ONO-5788 Placebo + OctreotideOno PharmaceuticalPhase 1
33
ONO-5788 + [14C]-ONO-5788Ono PharmaceuticalPhase 1
33
Pasireotide LARNovartisPhase 3
77
Octreotide acetate 30 mg suspensionNovartisPhase 3
77
Pasireotide long acting release formulationNovartisPre-clinical
23
Sandostatin LAR + pegvisomant + cabergolineNovartisApproved
85
Octreotide acetate and cabergoline/Octrotide and SomavertNovartisApproved
85
Sandostatin LARNovartisApproved
85
Pasireotide + OctreotideNovartisPhase 3
77
Sandostatin (Octreotide Acetate)NovartisApproved
85
Octreotide acetateNovartisApproved
85
Octreotide LARNovartisPhase 3
77
Octreotide LARNovartisPhase 3
77
PasireotideNovartisPhase 2
52
Pasireotide LAR 60 mg + PegvisomantNovartisApproved
85
OctreotideNovartisApproved
85
Octreotide LAR 30 MG InjectionNovartisApproved
85
Pasireotide LARNovartisPhase 2
52
Pasireotide (SOM230), Octreotide (Sandostatin)NovartisPhase 2
52

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85